The proposal for the decision on the incentive program has been presented as the Board of Directors considers it urgent, and in the interest of all shareholders, to create increased participation and incentives for the staff and any new recruitments. In addition, the program is considered to further increase the staff's result orientation while gathering the staff around a common goal decided by the Company. A notice for an extraordinary general meeting will be published in a separate press release.

The incentive program in brief

The incentive program gives employees of SyntheticMR the opportunity to subscribe for shares at market value in a directed issue. With each subscribed share, a share right is included, which entitles the holder to subscribe for two new shares for each share right after three years, provided continued employment and goal achievement. Employees will also have the opportunity to subscribe for ordinary warrants.

The subscription price for shares in the directed issue is determined by the volume-weighted average price (VWAP) and will be calculated during a trading period of 5 days following the decision on the directed new issue. After the stock market closes on the last day, the Company will inform the market about the applicable established price. In connection with the introduction of LTIP 2024, existing agreements regarding purchase options communicated on August 27, 2021, issued by the main owners to senior executives will expire, as the parties have jointly noted that these are without value.

At full utilization, the directed issue and associated share rights will result in a total dilution of a maximum of approximately 0.27 percent of the number of votes and capital. The warrants, at full utilization, can result in a dilution of a further maximum of approximately 0.36 percent of the total number of votes and capital. A separate incentive program will be introduced for an employee in the USA. The total dilution for that program will be 0.36 percent of the shares and votes in the Company. For more detailed information, please refer to the notice of the extraordinary general meeting that will be published in a separate press release.

For further information, please contact Ulrik Harrysson, CEO of SyntheticMR AB (publ).

Phone: +46 70 529 29 87

E-mail: ulrik.harrysson@syntheticmr.com.